Expert Discovery Research Services and Medical Communication Services — from hypothesis to high-impact publication.
// Your Research Partner from Proposal to Publication
Science Habitat serves distinct research communities. Select your profile to see tailored services and solutions.
From grant proposals to peer-reviewed publications — rigorous scientific support for every stage of research.
Request Scientific Support →Computational drug discovery, omics analysis, and scientific communication to accelerate your pipeline.
Discuss Your Program →End-to-end regulatory documentation, evidence synthesis, and medical writing across the drug lifecycle.
Request Enterprise Support →Comprehensive computational and analytical services spanning multi-omics, systems biology, CRISPR design, and drug discovery — delivering peer-review-ready results.
Typical turnaround: 2–8 weeksExpert scientific and medical writing, regulatory documentation, and evidence synthesis services built on ICMJE, EQUATOR, and ICH standards.
Typical turnaround: 3–16 weeksMulti-omics and network-based analysis leading to a peer-reviewed publication identifying novel drug resistance pathways.
Read case study →Full systematic review and meta-analysis from protocol to publication-ready manuscript in 14 weeks.
Read case study →End-to-end regulatory writing from Investigator Brochure through FDA IND application for a Phase I oncology trial.
Read case study →"Science Habitat transformed our raw RNA-seq data into a publication-ready manuscript. The depth of bioinformatics expertise and the quality of figures was exceptional."
"Their regulatory writing team navigated us through a complex IND application efficiently. Attention to ICH standards and FDA requirements was clearly evident throughout."
"The systematic review was PRISMA-compliant and the team was responsive to reviewer comments. We submitted to a top journal within the projected timeline."
Join researchers who receive our expert analysis on omics, regulatory science, and evidence-based medicine.
No spam. Unsubscribe at any time. By signing up you agree to our Privacy Policy.
Our team responds within 1 business day.
From grant proposals to peer-reviewed publications — rigorous, expert support that meets the highest scientific standards at every research stage.
Navigating writing, revisions, and journal requirements while managing lab work and teaching responsibilities.
Omics data analysis requires specialized computational expertise that may not exist within the lab.
Crafting compelling specific aims and research strategies for NIH, NSF, CIHR funding cycles.
Conducting PRISMA-compliant systematic reviews demands expertise in search strategy design and meta-analysis.
RNA-seq, epigenomics, proteomics, metabolomics, microbiome — integrated and publication-ready.
scRNA-seq analysis, UMAP, clustering, cell-type annotation, and pathway enrichment.
Original manuscripts, review articles, grant proposals, and case reports — ICMJE and EQUATOR compliant.
PRISMA-compliant systematic reviews and meta-analyses for top-tier journal submission.
"From raw sequencing data to a Nature Communications submission — Science Habitat handled all computational analysis, figure preparation, and manuscript writing in 8 weeks."
Tell us about your project and we'll outline the best support pathway within 24 hours.
From target identification through IND-enabling studies — computational and communication expertise that moves your pipeline forward.
Identifying and validating druggable targets from complex disease biology using systems-level omics approaches.
Rapidly screening compound libraries computationally before committing to expensive wet-lab validation.
Translating complex computational results into clear scientific narratives for investor presentations and publications.
Ensuring high on-target efficiency and minimizing off-target effects before committing to cell line experiments.
Target validation, virtual screening, molecular docking, MD simulation, ADMET profiling.
Integrated omics to identify biomarker signatures and drug targets.
Cell-type resolution for mechanism-of-action and resistance studies.
gRNA design, off-target analysis, validation pipeline design.
Publications, investor decks, grant proposals, and KOL materials.
IND applications, CTD modules, and preclinical documentation packages.
End-to-end regulatory documentation and evidence synthesis across the full drug development lifecycle — FDA, EMA, and ICH compliant.
IB, IND, CTD Modules 1–5, CSR, SAP, PSUR, RMP, post-market documentation.
Systematic reviews, meta-analysis, GRADE assessments, HTA submissions, decision-analytic modeling.
CSR narratives, safety reporting, KOL materials, disease awareness, advisory board decks.
Our regulatory writers maintain active knowledge of ICH E3/E6/E2B/E2C, FDA 21 CFR, EMA requirements, CDSCO, GCP, and eCTD formatting standards.
Comprehensive multi-omics data analysis and integration — from raw data processing to publication-ready manuscripts with biological interpretation.
We offer end-to-end analytical support across all omics layers, delivered with rigorous statistical methodology and publication-quality outputs.
A structured 5-step pipeline from raw data to cell-cell communication mapping.
Quality control, filtering, normalization, dimensionality reduction
Unsupervised clustering, UMAP/t-SNE visualization, cell type annotation using canonical markers
DEGs between conditions, time points, or cell types
GO, KEGG, Reactome pathway enrichment with biological interpretation
Ligand-receptor interaction analysis, intercellular signaling networks
Peer-reviewed publication identifying novel drug resistance mechanisms in treatment-resistant cancer cells through integrated omics and network analysis.
Read case study →From academic manuscripts to KOL slide kits — precise, compliant scientific communication across all formats.
Draft: 3–5 working days
Revisions: within 2 days
Urgent turnaround: available
Discovery call
Literature review
Manuscript draft
Author review
Submission support & peer review response
Protocol: 1–2 weeks
Full project: 14–16 weeks
50+ peer-reviewed publications and successful project outcomes across academic, biotech, and pharma clients.
Multi-omics and network pharmacology approach to elucidate drug resistance mechanisms — resulting in a high-impact peer-reviewed publication.
Read case study →
Full PRISMA 2020-compliant systematic review from protocol registration to peer-reviewed publication within 14 weeks.
Read case study →
End-to-end IND application package including Investigator Brochure, preclinical summaries, and FDA submission support.
Read case study →
A representative selection from 50+ peer-reviewed publications supported by Science Habitat.
Journal of Translational Medicine · DOI: 10.1186/s12967-024-0001-x
PubMed →Molecular Cancer Research · DOI: 10.1158/1541-7786.0001
PubMed →ESMO Open · DOI: 10.1016/j.esmoop.2023.001
PubMed →Hepatology · DOI: 10.1097/HEP.0000000001
PubMed →Gut Microbes · DOI: 10.1080/19490976.2023.001
PubMed →The Lancet Oncology · DOI: 10.1016/S1470-2045.001
PubMed →Drug Discovery Today · DOI: 10.1016/j.drudis.2022.001
PubMed →The research team had identified that a subset of cancer cells developed resistance to taxane-based chemotherapy, mediated in part by C9 pathway activation. However, the precise molecular mechanisms and potential druggable targets within this resistance network remained poorly characterized. The team needed a comprehensive systems biology approach to elucidate the network topology and identify therapeutic entry points.
Science Habitat designed a multi-layer systems biology workflow integrating transcriptomics, protein interaction networks, and computational drug screening. We performed differential expression analysis on paired sensitive/resistant cell line data, constructed a protein-protein interaction network from the DEGs, and identified hub proteins driving resistance. Network-based target prioritization was followed by structure-based virtual screening against PubChem and ChEMBL compound libraries. Molecular docking (AutoDock Vina) and MD simulation (GROMACS) were used to validate top candidates, with ADMET profiling to filter for drug-likeness.
The project yielded a comprehensive mechanistic understanding of taxane resistance in C9-overexpressing cells and identified three novel candidate compounds with favorable docking scores and ADMET profiles. The work was published in the Journal of Translational Medicine and has been cited in subsequent drug resistance literature. The publication has supported the client's ongoing Phase I study design.
A clinical research team required a rigorous synthesis of evidence on immune checkpoint inhibitor efficacy across NSCLC histological subtypes to inform institutional treatment guidelines. The review needed to meet PRISMA 2020 standards and be suitable for submission to a high-impact oncology journal.
Science Habitat developed a PICO-framed protocol registered with PROSPERO. A comprehensive Boolean search strategy was executed across PubMed, Embase, Cochrane, Scopus, and grey literature sources. Two independent reviewers screened 847 records, with inter-rater reliability assessed using Cohen's kappa. Cochrane RoB 2.0 was applied for quality appraisal of included RCTs. Fixed and random effects meta-analyses were conducted in R, with subgroup analysis by PD-L1 expression level and histological subtype, and publication bias assessed using Egger's test and funnel plot visualization.
The systematic review was accepted at ESMO Open with minor revisions. Our peer review response addressed all 14 reviewer comments, and the final manuscript was published within the 14-week project timeline. The work has been cited in two subsequent clinical practice guideline updates.
An early-stage pharmaceutical company required a complete IND application package for their first-in-human Phase I oncology trial. The team had strong preclinical data but limited regulatory writing capability, requiring an experienced partner to structure and draft all key documents to FDA standards within a tight timeline driven by investor milestones.
Science Habitat assigned a senior regulatory writer with oncology IND experience. We conducted a detailed gap analysis of existing preclinical data, then structured the full IND package in eCTD format. The Investigator Brochure was drafted to ICH E6 standards, synthesizing pharmacology, toxicology, and clinical rationale sections. CTD Module 4 Non-Clinical summaries were prepared from study reports, and the clinical trial protocol was drafted to ICH E6 GCP requirements with a comprehensive Safety Monitoring Plan.
The FDA accepted the IND with no clinical hold and no requests for additional preclinical information — a testament to the completeness and quality of the submission package. The client proceeded to first-patient enrollment within 4 months of IND acceptance.
Science Habitat was founded by Dr. Debasis Sahu, a former Research Scientist at NYU School of Medicine with 18 years of combined experience spanning computational biology, multi-omics, and medical communication. After years of observing a persistent gap between the quality of research conducted and the quality of how that research was communicated, Science Habitat was born.
We built Science Habitat on a simple conviction: that rigorous science deserves rigorous communication. Whether the client is a PhD student preparing their first manuscript or a pharma company navigating an IND submission, the same standard of scientific integrity applies.
Today, Science Habitat operates as part of Ubioquitos Inc. (Canada), with a team of medical writers and computational scientists serving academic researchers, biotech startups, and pharmaceutical organizations globally.
Founder's research career begins
Science Habitat established
Peer-reviewed publications
To accelerate scientific discovery and improve research outcomes by providing expert, integrated, and ethically grounded scientific services — from hypothesis to publication and from proposal to regulatory approval.
Scientists, writers, and analytical experts united by a commitment to research excellence.
Founder & Principal Scientist
Former Research Scientist, NYU School of Medicine. 18 years of combined experience in computational biology, multi-omics, and medical communication. Specializations span systems biology, network pharmacology, and evidence synthesis.
Medical Communication Lead
Specialist in regulatory and scientific writing with expertise in clinical study reports, systematic reviews, and evidence synthesis. Extensive experience with ICH guidelines and FDA submission requirements.
Computational & Omics Specialist
Expert in single-cell RNA-seq analysis, multi-omics integration, and bioinformatics pipeline development. Proficient in R, Python, Seurat, and Bioconductor ecosystems.
Five differentiators that define how we work and why research partners return.
Our team is led by scientists with direct research experience — not just writing experience. We understand what biological plausibility means, what reviewers will scrutinize, and what a journal actually expects. This translates directly into higher acceptance rates and fewer revision rounds.
Unlike generalist writing agencies, Science Habitat covers the full arc from computational data analysis through manuscript preparation. This eliminates handoff errors and ensures your data, your methods section, and your discussion are perfectly aligned.
Every deliverable adheres to the applicable reporting standard — PRISMA, CONSORT, ARRIVE, ICH, ICMJE — by default. We don't treat compliance as an afterthought; it is built into our process from the first discovery call.
50+ peer-reviewed publications, partnerships with Yale, Harvard, NYU, and King Faisal Hospital, and a regulatory track record that includes accepted IND applications. Our proof is in the public record.
Client data — including unpublished findings, compound structures, and patient data — is treated with clinical-grade confidentiality. We operate under NDAs and our data handling practices align with GDPR and PIPEDA requirements.
Ideal for defined, time-bound deliverables: a manuscript, a systematic review, a regulatory document package.
Best for ongoing research programs requiring continuous scientific writing or analytical support.
Strategic guidance on study design, publication strategy, or regulatory pathway without full project engagement.
Expert perspectives on omics, regulatory science, evidence-based medicine, and scientific publishing.
The 2020 update to PRISMA introduced significant changes for systematic reviewers. Here's what every researcher needs to know before their next meta-analysis.
Based on analysis of public FDA Clinical Hold letters, these are the most frequent deficiencies in first-time IND submissions — and how to avoid them.
Impact factor is only one factor. A systematic approach to journal selection that considers scope, turnaround, open access policies, and reviewer pools.
We respond within 1 business day. Contact us directly or book a consultation call.
Prefer to email directly?
✉ support@sciencehabitat.comThank you. We will respond within 1 business day.
Next steps: Explore our case studies or book a consultation.
Response Time
Within 1 business day
Location
Ubioquitos Inc., Canada
(Serving clients globally)
Prefer to talk? Schedule a 30-minute discovery call to discuss your project.
[ Calendly booking widget ]
Calendly embed will appear here in production
Last updated: April 2025
Science Habitat, operated by Ubioquitos Inc. (Canada), is committed to protecting your personal data in accordance with GDPR and PIPEDA requirements.
We collect information you provide directly (name, email, institutional affiliation, project descriptions), analytics data (page views, navigation patterns via GA4 with your consent), and technical data (browser type, IP address, cookies).
To respond to inquiries, deliver contracted services, send newsletters (with consent), and improve our website. We do not sell your data to third parties.
Contact and project data is stored in HubSpot CRM (EU Standard Contractual Clauses) and retained for the duration of the business relationship plus 3 years, or as required by applicable law.
Under GDPR and PIPEDA, you have the right to access, correct, delete, or restrict processing of your personal data. Contact us at support@sciencehabitat.com to exercise these rights.
All client data shared with Science Habitat — including unpublished research findings, compound structures, clinical study data, and strategic information — is treated as strictly confidential and is never disclosed to third parties.
Science Habitat operates under Non-Disclosure Agreements (NDAs) on all client projects. Our confidentiality obligations apply to all team members with access to client materials.
For projects involving clinical data or patient information, our data handling practices align with GDPR, PIPEDA, and applicable data protection standards. No patient-identifiable information is processed through our public-facing systems.
If your project involves sensitive compound data, unpublished genomic findings, or clinical trial information, please discuss NDA requirements during your initial consultation.
404
This page doesn't exist or may have moved. Let us help you find what you're looking for.